Mar 18, 2026

Pelage Pharmaceuticals’ PP405 and its Impact on Follicular Regeneration to be Presented at the American Academy of Dermatology (AAD) Annual Meeting 2026

LOS ANGELES – March 18, 2026 – Pelage Pharmaceuticals, a clinical-stage regenerative medicine biotechnology company, today announced that its first-in-class approach for treating hair loss with investigational medicine PP405 will be featured in a presentation about advances in the hair loss treatment landscape and regenerative mechanisms on Saturday, March 28th at the American Academy of Dermatology (AAD) Annual Meeting, taking place in Denver, Colorado.

Presentation Details:

Session: S020 New Innovations in Dermatology: What Devices and Treatments You Will Be Using in the Next 1-5 Years
Presentation: Emerging treatments for hair loss targeting dormant follicles
Presenter: Arash Mostaghimi, M.D., MPH, FAAD, Vice Chair of Clinical Trials and Innovation, Brigham and Women’s Hospital, Associate Professor, Harvard Medical School
Date: Saturday, March 28 at 10:15 a.m. MST

Treatments for hair loss and other dermatological conditions are undergoing an exciting period of innovation. Among the approaches with novel targets in clinical trials for androgenetic alopecia, PP405 is the most advanced and directly targets dormant hair follicle stem cells. As such, additional efficacy measurements may be helpful in assessing mechanisms aimed at follicle reactivation.

Follicular units are natural groupings of 1-5 hair follicles sharing nerve and vascular structure that grow in bundles on the scalp. While hair loss treatments have historically focused on increasing hair growth in already active follicular units, PP405 aims to additionally drive terminal (non-vellus) hair growth from previously dormant follicular units. The Follicular Unit Count quantifies the number of active hair follicular units with at least one hair. This method provides a more meaningful benchmark for assessing novel hair loss therapies and their ability to activate new follicular units.

The company previously reported Phase 2a topline results in which PP405 was well tolerated in men and women with no systemic absorption in a randomized controlled study. While dosing was limited to four weeks, results in men with a higher degree of hair loss showed a rapid and significant clinical response by week eight, four weeks after completion of treatment. New terminal hair was demonstrated to grow from previously dormant follicular units. Pelage expects to initiate late-stage studies in 2026, designed to further evaluate the safety and efficacy of PP405 in patients with androgenetic alopecia.

About Pelage Pharmaceuticals

Pelage Pharmaceuticals is a clinical-stage regenerative medicine biotechnology company developing first-in-class treatments for hair loss. With a focus on stem cell biology and metabolism, Pelage is advancing a novel class of therapies designed to reactivate dormant hair follicle stem cells and restore the body’s natural ability to grow hair. Its lead program, PP405, is currently in clinical trials for androgenetic alopecia. With its rigorous scientific foundation, Pelage is pioneering first-in-class hair-growth solutions for men and women of all hair types experiencing hair loss.

For more information about Pelage, visit https://pelagepharma.com/ and follow us on LinkedIn and X. To learn more about upcoming trials for PP405, sign up for updates at https://www.pelagepp405.com/.

Pelage Contact

Business development and investor inquiries: info@pelagepharma.com
Media inquiries: media@pelagepharma.com

About Pelage Pharmaceuticals

Pelage Pharmaceuticals is pioneering the first regenerative approach to hair loss, grounded in stem cell biology.

Pelage’s platform targets an intrinsic metabolic switch in hair follicles and is being developed for androgenetic alopecia and other forms of hair loss, with the aim of delivering a clinically tested, FDA-approved treatment suitable for all genders, skin types, and hair types.

Clinical Advisory Board

Arash Mostaghimi, M.D., M.P.A., M.P.H., F.A.A.D.

Vice Chair of Clinical Trials and Innovation, Director of the Dermatology Inpatient Service at Brigham & Women’s Hospital
Associate Professor of Dermatology, Harvard Medical School

Dr. Arash Mostaghimi is the Vice Chair of Clinical Trials and Innovation and Director of the Consult Service for the Department of Dermatology at Brigham & Women’s Hospital. With board certifications in dermatology, internal medicine, and clinical informatics, Dr. Mostaghimi is an active clinician with an emphasis on complex medical dermatology and hair loss disorders. As a clinical researcher, Dr. Mostaghimi has over 275 peer reviewed publication, and served as a principal investigator involved in the design and implementation of numerous clinical trials. He has received numerous teaching and mentorship awards and is co-director of the Complex Medical Dermatology Fellowship.

Clinical Advisory Board

Amy McMichael, M.D., F.A.A.D.

Professor and Past Chair of Dermatology, Wake Forest School of Medicine

Dr. Amy McMichael is a Philadelphia native who received her medical degree from the University of Pennsylvania School of Medicine. She completed Dermatology residency training at the University of Michigan School of Medicine.

Dr. McMichael is a Professor in the Department of Dermatology at Wake Forest School of Medicine in Winston-Salem, NC. She has held leadership positions in the Department for over 20 years first as Residency Program Director for 12 years and Chair of the Department for 11 years. She has been a leader in her field, including her roles as past President of Skin of Color Society and past President of the National Medical Association Dermatology Section. She recently served as a Board member of the American Academy of Dermatology.
Dr. McMichael’s clinical and research interests include: hair and scalp disorders, psoriasis, and skin of color. She is co-editor of several medical

Clinical Advisory Board

Mathew Avram, M.D., J.D., F.A.A.D.

Director of the Dermatology Laser & Cosmetic Center, Massachusetts General Hospital
Associate Professor of Dermatology, Harvard Medical School

Dr. Mathew M. Avram is the Director of the Massachusetts General Hospital Dermatology Laser & Cosmetic Center and serves as Faculty Director for Dermatology Cosmetic Training at Harvard Medical School. He is the Past-President of both the American Society for Dermatologic Surgery and American Society for Laser Medicine & Surgery. Dr. Avram has co-authored 7 textbooks and 90 peer-reviewed publications. Dr. Avram has delivered over 800 invited lectures, co-chaired teaching sessions for the FDA for three years, and has two U.S. patents. Dr. Avram has been recognized by Newsweek as one of the Top 10 cosmetic dermatologists in America.

Clinical Advisory Board

Amelia K. Hausauer, M.D., F.A.A.D.

Director of Dermatology and Minimally Invasive Aesthetics at Aesthetx

Dr. Amelia K. Hausauer is the Director of Dermatology and Head of Aesthetic Medicine at Aesthetx, a hybrid dermatology and plastic surgery practice in Northern California. She is a key opinion leader for early pipeline innovation and development of multiple injectable and regenerative therapies as well as an active research investigator. Dr. Hausauer spearheaded one of the largest clinical trials using PRP for hair growth and served as the chief editor for Platelet Rich Plasma (PRP) and Microneedling in Aesthetic Medicine. Earning a bachelor’s degree from Stanford University and medical doctorate from University of California San Francisco, Dr. Hausauer completed residency at New York University then an American Society for Dermatologic Surgery cosmetic surgery fellowship.

Leadership

Qing Yu Christina Weng, MD

Chief Medical Officer

Chief Medical Officer

Dr. Weng is the CMO of Pelage. She is a physician-scientist and entrepreneur, board-certified dermatologist, and Lecturer at Harvard Medical School. She is experienced in corporate startup strategy as Head of Business Development & Strategy at Kira Pharma and CSO and cofounder of Mymiel Skincare. She is on the Board of Directors for the Dermatology Innovation Forum and Dermatology Summit. Dr. Weng has an undergraduate degree from the California Institute of Technology, MD from Harvard, and she completed dermatology residency and fellowship at Harvard.

Leadership

Daniel Gil, PhD

Chief Executive Officer

Chief Executive Officer

Dr. Gil is the CEO of Pelage. He is also a Venture Partner with Visionary Ventures. Until 2018, Dr. Gil was a Vice President at Allergan, overseeing the research portfolio and early clinical development. His research contributed to development of 5 marketed drugs and he led 8 clinical development projects. He is an inventor on 70+ issued US patents and author on 45 peer-reviewed research articles. Dr. Gil has an undergraduate degree in Biology from Harvard University and a PhD in Pharmacology from the University of Pennsylvania.

Leadership

Michael Jung, PHD

Co-Founder

Co-Founder
Professor, UCLA Chemistry & Biochemistry

Dr. Jung is a renowned Medicinal Chemist and co-founder of several successful startups. He is also co-inventor of two FDA approved drugs for prostate cancer (Xtandi & Erleada) with several drugs currently in clinical trials.

Leadership

Heather Christofk , PhD

Co-Founder

Co-Founder
Professor, UCLA Biological Chemistry

Dr. Christofk is a leader in the metabolism field with a research focus on how metabolism regulates cell state transitions. Her groundbreaking collaborative research with Dr. Lowry revealed that changes in metabolism can instruct hair follicle stem cell activation, forming the basis for the Pelage’s approach to treat hair loss. She is a Professor of Biological Chemistry at the David Geffen School of Medicine at UCLA and Associate Director of Basic and Translational Research at the UCLA Jonsson Comprehensive Cancer Center. She earned her bachelor’s degree from UCLA, her PhD from Harvard, and conducted postdoctoral research at UCSF before joining the faculty at UCLA in 2008.

Leadership

William Lowry, PhD

President & Co-Founder

President & Co-Founder
Professor, UCLA Molecular, Cell and Dev. Biology

Dr. Lowry is a leader in the stem cell field with 20+ years of research experience resulting in the discovery that hair follicle stem cells can be activated by metabolic manipulation. His work has led to the creation of several startups including Pelage and Sardona, as well as other efforts under development.